Important role of raft aggregation in the signaling events of cold-induced platelet activation  by Gousset, Karine et al.
www.bba-direct.com
Biochimica et Biophysica Acta 1660 (2004) 7–15Important role of raft aggregation in the signaling events of
cold-induced platelet activation
Karine Gousseta,b,*, Nelly M. Tsvetkovaa,c, John H. Crowea,c, Fern Tablina,b
aCenter for Biostabilization, University of California, Davis, CA 95616, USA
bDepartment of Anatomy, Physiology and Cell Biology, School of Veterinary Medicine, University of California, Davis, CA 95616, USA
cSection of Molecular and Cellular Biology, University of California, Davis, CA 95616, USAReceived 8 July 2003; received in revised form 18 September 2003; accepted 19 September 2003Abstract
When human platelets are chilled below 20 jC, they undergo cold-induced activation. We have previously shown that cold activation
correlates with the main phospholipid phase transition (10–20 jC) and induces the formation of large raft aggregates. In addition, we found
that the glycoprotein CD36 is selectively enriched within detergent-resistant membranes (DRMs) of cold-activated platelets and is extremely
sensitive to treatment with methyl-h-cyclodextrin (MhCD). Here, we further studied the partitioning of downstream signaling molecules
within the DRMs. We found that the phospholipase Cg2 (PLCg2) and the protein tyrosine kinase Syk do not partition exclusively within the
DRMs, but their distribution is perturbed by cholesterol extraction. In addition, PLCg2 activity increases in cold-activated cells compared to
resting platelets and is entirely inhibited after treatment with MhCD. The Src-family protein tyrosine kinases Src and Lyn preferentially
partition within the DRMs and are profoundly affected by removal of cholesterol. These kinases are non-redundant in cold-activation. CD36,
active Lyn, along with inactive Src and PLCg2 co-localize in small raft complexes in resting platelets. Cold-activation induces raft
aggregation, resulting in changes in the activity of these proteins. These data suggest a crucial role of raft aggregation in the early events of
cold-induced platelet activation.
D 2003 Elsevier B.V. All rights reserved.Keywords: Raft; Signaling; Platelet; Microdomain; Protein tyrosine kinase; Cyclodextrin1. Introduction
The lateral organization of lipids in cellular membranes,
due to preferential packing, has led to the concept of lipid
microdomain formation. It has been suggested that sphin-
golipids and cholesterol could form a ‘‘sorting platform-
like-structure’’, or raft, in the lipid bilayer in which proteins
could be selectively included or excluded [1]. Most of the
early studies on rafts have relied heavily on the use of cold
non-ionic detergent extraction and model membrane sys-
tems [2–4]. The insolubility of these membrane micro-
domains in non-ionic detergents such as Triton X-100 is
thought to reflect the physical properties of these specific0005-2736/$ - see front matter D 2003 Elsevier B.V. All rights reserved.
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E-mail address: kgousset@jhu.edu (K. Gousset).lipid/protein assemblies. Indeed, it was postulated that in
membranes, rafts exist as domains in the liquid-ordered
phase [2,5–7]. The high melting temperature of sphingoli-
pids could promote phase separation and formation of
liquid-ordered domains in the presence of high amount of
cholesterol. Using model membranes, it was determined that
only pre-existing liquid-ordered domains are insoluble in
Triton X-100 [5,7]. The use of detergent extraction is now
well established, and many signaling molecules have been
found to be associated with these detergent-resistant mem-
branes (DRMs) [8–11].
When platelets are chilled from 37 to 4 jC, they
undergo cold-induced activation. In order to avoid this
phenomenon, blood banks are forced to store human
platelets at room temperature (22 jC) for only 3 to 5 days
since prolonged storage often results in bacterial over-
growth [12]. To avoid any contamination, federal regula-
tions require the destruction of all stored platelets after 5
days, which can create a chronic shortage of transfusable
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physiological agonists, chilled platelets change shape
[14,15], demonstrate an increase in F-actin [16,17] and a
rise in cytosolic calcium [17–20]. In addition, physiolog-
ical platelet activation also induces tyrosine phosphoryla-
tion of many cytosolic proteins, including phospholipase
C-g2 (PLCg2) and the non-receptor tyrosine kinase Syk
[21,22]. Dorahy and colleagues [24,25] have noted the
presence of the two non-receptor tyrosine kinases Src and
Lyn in DRMs isolated from resting platelets as well as the
selective partitioning of the platelet glycoprotein CD36
within this fraction. Our laboratory has previously shown
that microdomains or rafts exist in human platelets at
physiological temperatures and coalesce to form macro-
domains during activation [26]. These events were disrup-
ted by treatment with methyl-h-cyclodextrin (MhCD),
which collapses the rafts by removing cholesterol from
the plasma membrane [27,28]. The DRMs were enriched in
cholesterol and sphingomyelin and showed two thermal
phase transitions around 15 and 30 jC, assigned to the
phospholipids and the sphingomyelin-enriched rafts, re-
spectively [26]. To determine whether raft aggregation
mediates signal transduction by clustering receptors and/
or signaling molecules, we studied the partitioning of the
GPI-anchored protein CD55, and the two major platelet
receptors, CD36 and the integrin aIIb, into DRMs isolated
from cold-activated platelets. Similar to the findings of
Huang et al. [23], we found that CD36 partitions within the
DRMs of resting and cold-activated platelets, and is ex-
tremely sensitive to the presence of cholesterol in the
plasma membrane. In contrast, the partitioning of both
CD55 and the integrin aIIb is not restricted to the DRMs
and is not affected by the removal of cholesterol [26].
These results imply that proteins are selectively included
within the DRMs and suggest an important role of raft
aggregation in platelet activation.
In this study, we further investigated the function of raft
aggregation in cold-induced platelet activation, determining
the partitioning of downstream signaling molecules such as
PLCg2, Syk, Src and Lyn into the DRMs. While their
partitioning is a selective event, independent of cell acti-
vation, their activity was found to be directly regulated by
this process. Furthermore, we showed that the surface
protein CD36, along with PLCg2, Src and Lyn, is associ-
ated into raft complexes in resting platelets prior to raft
aggregation and cell activation as well as in cold-activated
platelets.2. Materials and methods
2.1. Isolation of DRMs
Platelet concentrates were obtained from the Sacra-
mento Blood Center and incubated overnight with 10 Ag/
ml prostaglandin E1 (PGE1) at 25–30 jC. Platelet-richplasma was obtained by spinning the cells at 1400 rpm for
10 min at 30 jC. First, the cells were washed with Buffer
A (100 mM NaCl, 10 mM KCl, 10 mM EGTA, 10 mM
imidizole, pH 6.8) containing 10 Ag/ml PGE1 and then
again with warm TKM buffer (50 mM Tris–HCl, 25 mM
KCl, 5 mM MgCl and 1 mM EGTA, pH 7.2) containing
10 Ag/ml PGE1.
Washed platelets were first incubated at 37 jC with or
without 10 mM MhCD for 1 h, and then they were
incubated 4 jC for 1 h. Control cells were incubated for
2 h at 37 jC. Prior to fractionation, platelets were mixed
with a cocktail of protease inhibitors (2 mg/ml of leupeptin
(Calbiochem Novabiochem Corp., La Jolla, CA), 5 mM
Pefa-Bloc (Roche Molecular Biochemicals, Indianapolis,
IN), 1% aprotinin (Sigma, St. Louis, MO), 1% pepstatin A
(Roche Molecular Biochemicals) and 100 nM benzamidine
(Sigma)) and 2 mM of the activated tyrosine phosphatase
inhibitor sodium orthovanadate (Sigma). The cells, mixed
(1:1) with ice-cold 80% sucrose-TKM to obtain a final
mixture of 40% sucrose, were then lysed with 1% Triton
X-100 and incubated at 4 jC for 20 min. Two milliliters of
cell lysates was overlaid with 6.6-ml 36% sucrose-TKM
and 3.3-ml 5% sucrose-TKM and were centrifuged at
200,000 g for 20 h at 4 jC using a swinging bucket
rotor (SW41 ti) (Beckman). Samples from the 5%, 36%
sucrose-TKM and the insoluble pellet were used for
analysis. The DRMs were collected at the interface of
the 5% and 36% sucrose-TKM and were washed in cold
PBS (10 mM sodium phosphate, 150 mM sodium chloride,
pH 7.2) followed by centrifugation at 42,000 g for 90
min at 4 jC.
2.2. Antibodies, SDS-PAGE and Western blotting analysis
Monoclonal mouse antibody CD36 was a generous gift
from Dr. Narendra N. Tandon (Otsuka America Pharmaceu-
tical Inc., Rockville, MD). Monoclonal mouse antibodies to
Lyn and Syk and polyclonal rabbit antibody to PLCg2 were
purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz,
CA), whereas the monoclonal mouse antibody Src (clone
GD11) was obtained from Upstate Biotechnology (Lake
Placid, NY). For the Western blots, we used the following
secondary antibodies: goat anti-mouse IgG, alkaline phos-
phatase conjugate (Pierce, Rockford, IL) for Syk, Lyn and
Src, and goat anti-rabbit IgG, alkaline phosphatase conju-
gate (Pierce) for PLCg2.
DRM fractions were mixed with reducing Laemmli
buffer, boiled, separated by SDS-PAGE [29] and transferred
onto PVDF (Bio-Rad Laboratories, Hercules, CA) mem-
branes using a Bio-Rad mini trans-blot [30]. Membranes
were blocked using 5% non-fat dry milk in Tween 20–TBS
buffer (0.5% Tween, 10 mM Tris–base pH 7.4, 150 mM
NaCl) for 1 h at 4 jC. The fractions were assayed for
PLCg2, CD36, Syk, Src or Lyn. The bound antibodies were
detected by chemiluminescence (CDP-Star, Roche Molecu-
lar Biochemicals).
Fig. 1. PLCg2, Syk, Src and Lyn distribution in DRMs isolated from cold-
activated platelets. (A) Schematic of the sucrose density fractionations.
Platelets lysed with Triton X-100 in a 40% sucrose mixture are layered with
36% and 5% sucrose buffer and centrifuged for 20 h at 200,000 g (4 jC).
The DRMs can be visualized between 5% and 36% sucrose interface. (B)
Samples from each fraction were run on polyacrylamide gradient gels. The
samples, resolved by SDS-PAGE, were transferred to PVDF membranes for
Western blot analysis. No protein was detected in the 5% sucrose fraction
(data not shown). Fractions were evenly loaded based on total protein
content. However, the insoluble pellet cannot be broken down. Therefore,
the last two lanes can only be used in a qualitative manner. Both PLCg2 and
Syk are present in all fractions, but decrease sharply in the DRMs after
treatment with MhCD (61% and 28% reduction, respectively). Upon
treatment with MhCD, the amount of PLC-g and Syk only increase by
6.5% and 5.3%, respectively, in the 36% sucrose fraction. The two Src-
family kinases Src and Lyn, however, are greatly enriched in DRMs, and
are extremely sensitive to removal of cholesterol within this fraction. Src
and Lyn are reduced by 83% and 44%, respectively, after treatment with
MhCD. These results suggest that most of the proteins lost after treatment
with MhCD are recovered in the insoluble pellet.
Fig. 2. PLCg2, CD36, Syk, Src and Lyn are present in DRMs from resting
and cold-activated-platelets. Western blot analysis of DRMs isolated from
resting and chilled platelets shows that there is no drastic redistribution of
PLCg2, CD36, Syk, Src or Lyn after activation. PLCg2 increases by 25%
after cold-induced activation, whereas both Syk and CD36 decrease by 19%
and 29%, respectively. The distribution of Src and Lyn was not affected by
cell activation.
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membranes were blocked with 1% BSA in low salt Tween
20–TBS buffer (0.1% Tween, 10 mM Tris–base pH 7.5, 50
mM NaCl) overnight at 4 jC. The membranes were incu-
bated with anti-phosphotyrosine antibody conjugated to
alkaline phosphatase (RC-20) (Transduction Laboratories,
Lexington, KY) for 30 min at 37 jC and detected by
chemiluminescence.
2.3. Immunoprecipitation and protein kinase assay
The platelets were lysed at 4 jC for 30 min in Buffer A
containing 1% Triton X-100, 2 mg/ml of leupeptin (Calbio-
chem Novabiochem), 5 mM Pefa-Bloc (Roche Molecular
Biochemicals), 1% aprotinin (Sigma), 1% pepstatin A(Roche Molecular Biochemicals), 100 nM benzamidine
(Sigma) and 2 mM of activated sodium orthovanadate
(Sigma). DRMs or platelets lysates from resting or cold-
activated platelets (FMhCD) were pre-cleared with either
mouse IgG-conjugated beads or rabbit IgG-conjugated
beads (Santa Cruz Biotechnology) for 30 min at 4 jC.
The beads were pelleted at 1000 g for 5 min at 4 jC. The
supernatants were incubated with anti-Syk-agarose-conju-
gated beads (Santa Cruz Biotechnology) overnight at 4 jC.
For CD36 or PLCg2 immunoprecipitation, the supernatants
were first incubated with either CD36 monoclonal antibody
or PLCg2 polyclonal rabbit antibody for 1 h at 4 jC,
followed by the addition of Protein-G-agarose (Calbiochem)
and incubated overnight at 4 jC. For Lyn and Src, the
supernatants were incubated with either Lyn or Src antibody
agarose-conjugated beads (Santa Cruz Biotechnology) for
90 min at 4 jC.
For all five proteins, the beads were collected by centri-
fugation at 1000 g for 5 min at 4 jC. The pellets were
washed twice with ice-cold RIPA buffer (50 mM Tris–HCl,
pH 7.4, 1% NP-40, 0.25% Na-deoxycholate, 150 mM NaCl,
1 mM EDTA, 1 mg/ml of aprotinin, leupeptin, and pep-
statin, and 1 mM Na3VO4) and twice with ice-cold PBS.
After the final wash, the pellets were resuspended in 50 Al of
PBS.
Aliquots for PLCg2, CD36, Syk, Src and Lyn were used
for Western blot analysis. Aliquots for Lyn and Src were
also used in a non-radioactive protein tyrosine kinase assay
(Roche, Molecular Biochemicals). This photometric enzyme
immunoassay uses streptavidin-coated microtiter plates, a
synthetic biotin-labeled substrate peptide and a highly
specific anti-phosphotyrosine antibody conjugated to per-
oxidase. The assay is very sensitive with a detection down
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The color intensity is directly proportional to the enzyme
activity and can be measured using the absorbance of the
sample at 405 nm on a microtiter plate reader. The assays
were run according to the manufacturer’s Kit Protocol. The
assay buffer contained 20 mM HEPES/NaOH, 10 mM
MgCl2, 3 mM MnCl2, pH 7.2. The enzymes reactions were
carried out for 30 min at 37 jC.3. Results
3.1. Selective partitioning of cytosolic proteins during DRM
isolation from cold-activated platelets
It has previously been shown that the partitioning of
proteins into DRMs isolated from platelets using Triton X-
100 was similar to that isolated with a detergent-free
method [24,25]. In this study, we used detergent extractionFig. 3. Level of activity of PLCg2 and Syk in DRMs. (A) DRMs were obtained
platelets; (2) DRMs of cold-activated platelets; (3) DRMs of cold-activated pla
separated by SDS-PAGE and electrotransferred onto PVDF membranes. The m
phosphorylation. The membranes were then stripped with h-mercaptoethanol stripp
for 50 ml solution) for 20 min at 70 jC, and probed for PLCg2 or Syk. Lanes (1
proteins based on densitometry of the Western blots for each condition. (1) In
phosphorylated in cold-activated platelets (2). However, almost 15% of Syk becom
(2), twice as much PLCg2 is phosphorylated compared to resting platelets (1). Dand sucrose density gradients in order to obtain DRMs from
resting or cold-activated platelets (Fig. 1A). In addition, we
were able to isolate DRMs from platelets treated with
MhCD and chilled to 4 jC by increasing the concentration
of platelets by a factor of 5. We have previously shown that
the DRMs from cold-activated platelets, found at the
interface of the 5–36% interface (Fig. 1A), are highly
enriched in CD36 [26]. Here we studied the partitioning
of cytosolic proteins in cold-activated platelets and identi-
fied the subsequent changes in protein distribution after
treatment with MhCD. Western blot analysis from the
DRMs, 36% sucrose and the insoluble pellet, obtained
during DRMs isolation, shows that both PLCg2 and Syk
partition into the 36% and the insoluble pellet, and are not
only restricted to the DRMs (Fig. 1B). However, the
partitioning of both proteins was affected by pretreating
the cells with MhCD. Indeed, we observed a decrease of
61% for PLCg2 and of 28% for Syk in the DRMs after
treatment with MhCD. Contrary to what had been foundfrom resting and cold-activated platelets (FMhCD). (1) DRMs of resting
telets pretreated with MhCD. PLCg2 and Syk were immunoprecipitated,
embranes were probed with anti-tyrosine antibody to determine tyrosine
ing buffer (62.5 mM Tris–HCl, pH 6.8, 2% SDS, 340 Al h-mercaptoethanol
–3) should only be compared qualitatively. (B) Percent of phosphorylated
resting platelets, Syk is dephosphorylated and only 5% of the protein is
es phosphorylated upon removal of cholesterol (3). In cold-activated cells
isrupting the rafts with MhCD blocks PLCg2 phosphorylation.
Fig. 4. Kinase activity of Src and Lyn as a function of cell activation. The
activity of immunoprecipitated Lyn (A) and Src (B) from DRMs isolated
from resting (1), cold-activated platelets (2) or chilled platelets pretreated
with MhCD (3) were determined using a photometric enzyme immuno-
assay. The moles of phosphorylated substrate ( 10 13) per minute per
milligram of enzyme was plotted for each condition. (A) The levels of
activity of Lyn were similar in DRMs from resting (1) and cold-activated
cells treated with MhCD (2). One milligram of Lyn phosphorylated
76 10 13(F 16) mol substrate/min (1), compared to 93 10 13(F 11)
mol substrate/min (3). In cold-activated platelets, however, Lyn activity
decreases by two (2). (B) On other hand, Src was found to be up-regulated
in DRMs from chilled platelets, 1 mg of enzyme phosphorylating
285 10 13(F 73) mol substrate/min. This level of activation was over
2.5 times higher than the basal level obtained for DRMs from resting
platelets (110 10 13F 15) or that of MhCD treated platelets (131
10 13F 68) (1, 3).
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like CD36, the two Src-related proteins Src and Lyn
preferentially partition within the DRMs of cold-activated
platelets (Fig. 1B). In addition, both tyrosine kinases were
extremely sensitive to treatment with MhCD, with a loss of
83% for Src and 44% for Lyn from the DRM fractions after
removal of cholesterol. Our data identify these four cyto-
solic proteins as potentially important ‘‘raft-signaling’’
proteins in cold-induced platelet activation.
3.2. Partitioning of proteins in DRMs isolated from resting
and cold-activated platelets
If PLCg2, Syk, Src, Lyn, along with the transmembrane
receptor CD36, play an important role in cell activation via
raft aggregation, then either the proteins’ partitioning and/or
the enzyme’s activities must be different in resting versus
cold-activated platelets. Since we have shown that small,
individual rafts exist in resting platelets [26], we first
determined whether cell activation induces a change in the
protein composition of the DRMs. Fig. 2 shows that there
are no drastic changes in the partitioning of the cytosolic
proteins or CD36 in DRMs isolated from resting or cold-
activated platelets. In chilled platelets, PLCg2 increases by
26%, whereas both CD36 and Syk decrease by 28% and
20%, respectively. On the other hand, the partitioning of Src
and Lyn was not affected by cell activation. Overall, these
results show that cold-induced activation does not lead to a
significant redistribution of these proteins in the DRMs.
3.3. PLCc2 is an important ‘raft signaling’ molecule in
cold-activated platelets
The next step was to determine the activation state of
PLCg2, Syk, Src and Lyn. Syk is not phosphorylated in
resting platelets, but was found to be rapidly and transiently
activated by the platelet agonist thrombin [31]. In platelets,
Syk undergoes early activation in an integrin-independent
mechanism, and subsequent activation as a function of
integrin clustering [32]. Collagen activation results in the
tyrosine phosphorylation of multiple cytosolic proteins
including Syk followed by PLCg2 [33–36]. Here, we
immunoprecipitated PLCg2 and Syk from DRMs isolated
from resting and cold-activated platelets (FMhCD) and
assessed tyrosine phosphorylation by Western blot analysis
(Fig. 3A). The percent of phosphorylated proteins is plotted
as a function of temperature for each condition (Fig. 3B). In
resting platelets, Syk is dephosphorylated, whereas in cold-
activated platelets, only 5% of the protein is phosphorylated.
However, upon cholesterol depletion, almost 15% of Syk
becomes phosphorylated. In contrast, PLCg2 shows a very
different pattern of tyrosine phosphorylation in the DRMs.
Indeed, PLCg2 is two times more active in DRMs isolated
from cold-activated platelets, compared to DRMs from
resting platelets. Furthermore, removal of cholesterol leads
to complete inhibition of its activity, identifying PLCg2 asan important ‘‘raft signaling’’ protein in cold-induced plate-
let activation.
3.4. Lyn tyrosine kinase is down-regulated, whereas Src is
up-regulated in DRMs from cold-activated platelets
The Src-related family kinases are known to have mul-
tiple tyrosine phosphorylation sites [37–41]. They can
either be repressed if phosphorylated at their C-terminus
or activated if phosphorylated in their catalytic domains.
Therefore, a tyrosine kinase assay is necessary to determine
their activity. Falati et al. [42] have shown that Lyn is one of
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of both Syk and PLCg2 in platelets activated by von
Willebrand factor. Lyn also plays a key role in collagen
activation [43,44]. Finally, the kinase activity of both Lyn
and Src, which is the most abundant protein tyrosine kinase
in platelets [45], was altered in DRMs isolated from resting
versus thrombin-activated platelets [25]. Using a photomet-
ric enzyme immunoassay, we found Lyn to be two times
more active in DRMs isolated from resting cells compared
to DRMs from cold-activated platelets (Fig. 4A). Upon
removal of cholesterol, the activity of Lyn is restored to
that of DRMs from resting platelets (f 80 10 13 mol
phosphorylated substrate/min/mg enzyme). These results
demonstrate that the activity of Lyn strongly depends on
raft aggregation and that Lyn is down-regulated in cold-
activated platelets. The pattern of activity for Src was
opposite to that observed for Lyn. Indeed, we determined
Src to be 2.6 times more active in DRMs of cold-
activated cells, compared DRMs of resting platelets
(Fig. 4B). Furthermore, treatment with MhCD, reduces
the level of Src activity to that of DRMs from resting
platelets (f 100 10 13 mol phosphorylated substrate/
min/mg enzyme). These results demonstrate that Src is an
important signaling molecule in cold-induced activation of
platelets. Whereas Lyn was found to be down-regulated in
chilled cells, Src is up-regulated in cold-activated plate-
lets, demonstrating that these tyrosine kinases are not
functionally redundant.
3.5. CD36, PLCc2, Lyn and Src are part of a ‘‘raft
complex’’
In platelets, as well as in human melanoma and HeLa
cells, Huang et al. [23] have shown that the surface receptor
CD36 is physically associated with Fyn, Lyn and Yes, three
Src-related tyrosine kinases. They noted that Src association
to this complex depends upon the lysis buffer used during
platelets’ solubilization. Since we showed that CD36,Fig. 5. Association of CD36, Src, Lyn and PLCg2 in rafts. Platelet lysates from r
immunoprecipitated for CD36, Src and Lyn. The samples were resolved by SDS-PA
and Lyn. All four proteins were pulled down in all three immunoprecipitations, sug
cells.PLCg2, Lyn and Src partition into the DRMs of resting
and cold-activated platelets, we further studied whether
these four proteins would form a raft complex. In order to
maintain the lipid–protein interactions of the plasma mem-
brane, SDS was not added to the lysis buffer [46–48].
Similar to the platelet lysates obtained for DRMs isolation,
resting and cold-activated platelets were lysed with Triton
X-100, immunoprecipitated for CD36, Src and Lyn, and
separated by gel electrophoresis. Western blot analysis
shows that all four proteins are present in CD36-, Lyn- or
Src-immunoprecipitations, independently of the activated
state of the platelets (Fig. 5). These data suggest that these
proteins are associated into a raft complex both in cold-
activated and in resting platelets.4. Discussion
Our data suggest that raft aggregation is a selective
process, dependant upon the physical state of the membrane.
In this study, we showed that PLCg2, Src and Lyn are key
signaling molecules in cold-activated platelets. Removal of
cholesterol from raft domains results in profound alterations
in the distribution of these three proteins.
Collagen activation of human platelets induces tyrosine
phosphorylation of both PLCg2 and Syk [37–41]. Here, we
showed that tyrosine phosphorylation of PLCg2, which is
closely associated with aggregated rafts, also increases in
the cold. Surprisingly, tyrosine phosphorylation of Syk,
which increases in the cold, triples after the collapse of
the rafts. This suggests that cholesterol directly affects the
partitioning and/or the activity of cytosolic proteins. Our
data identify PLCg2 as a key molecule in the signaling
pathway of cold-activated platelets, since it appears to be
regulated by a ‘‘raft tyrosine kinase’’. On the other hand,
there is an increase in Syk phosphorylation only after
removal of cholesterol. In both cases, however, the fact that
protein phosphorylation either drastically increased or de-esting and cold-activated platelets were solubilized with Triton X-100, and
GE, transferred onto PVDF membranes and probed for CD36, PLCg2, Src
gesting that they are part of a raft complex in resting, as well as in activated
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shows that there is a correlation between formation of a
liquid-order phase and the selective partitioning of lipids
and proteins into the membrane domains. The Src family-
specific inhibitor PP1 has been shown to inhibit both Syk
and PLCg2 phosphorylation in platelets with activated
glycoprotein Ib [42], as well as in collagen- and convul-
xin-activated platelets [49]. In cold-induced activation, our
data suggest that kinases, such as Src, and phosphatases
regulate the activity of both Syk and PLCg2 depending on
the fluidity of the membrane.
Similarly to the data of Dorahy and Burns [25] compar-
ing resting platelets versus thrombin-activated platelets, we
show here that Src is highly active in cold-activated plate-
lets, whereas Lyn is down-regulated after chilling. Activa-
tion of proteins from the Src-related family requires the
binding of proteins to their SH2 and SH3 domains, which
allows for conformational changes and phosphorylation of a
conserved tyrosine residue in their catalytic domain
[38,41,50]. Therefore, in order to obtain the changes in
the kinase activity observed during chilling, raft aggregation
had to affect directly the partitioning of a number of
cytosolic proteins, including adapter molecules, kinases
and phosphatases. A good candidate for Lyn regulation is
the Csk homologous kinase (Chk), which has been shown to
regulate negatively CD36-anchored Lyn in thrombin-acti-
vated platelets by phosphorylation of Tyr508 on its carbox-
yl-terminal end [51]. Overall, our data clearly demonstrate
that raft aggregation and partitioning of proteins withinFig. 6. Model for raft aggregation in cold-induced platelet activation. At 37 jC, raft
and PLCg2 are associated within these cholesterol-enriched microdomains. Upon ch
platelet change shape occurs, there is an increase in cytosolic calcium, and large agg
for the clustering of signaling molecules necessary for signal transduction to occur
activation of Src and PLCg2, and Lyn inactivation.these lipid domains is a selective, dynamic process regulated
by the cell and necessary for cell signaling.
Based on these results, we propose the following model
for cold-induced platelet activation (Fig. 6). Small, non-
functional rafts exist in resting platelets (at 37 jC). These
individual rafts are too small to be visualized by conven-
tional microscopy, but can be detected using spectroscopic
methods, such as Fourier transform infrared spectroscopy
[26]. CD36, active Lyn, along with inactive Src and PLCg2
are part of raft signaling complex. Upon cold-induced
platelet activation, the cells change shape, and rafts coalesce
into large macrodomains, visible by fluorescence microsco-
py [26]. In platelets, the primary role of CD36 is still
unclear. CD36 has been shown to form multimers [52],
which may increase the stability of the aggregated domains.
Another possible role of CD36 in raft signaling may be to
induce conformational changes of associated Src-related
kinases [23]. The formation of these larger, more stable
domains would allow for the clustering of the signaling
molecules that trigger downstream signaling events, dephos-
phorylation of Lyn, and phosphorylation of both PLCg2 and
Src.
Finally, cold-induced activation in platelets is associated
with cell shape change [14] and correlates with an increase
in cytosolic calcium [18]. Suzuki-Inoue et al. [53] have
shown that activation of Src, along with phosphorylation of
both Syk and PLCg2 in platelets activated by the agonist
Rhodocytin, purified from the Calloselasma Rhodostoma
venom [54], requires actin polymerization. In HeLa cells ass exist but are too small to be functional. CD36, active Lyn, and inactive Src
illing of the platelets through the phospholipids phase transition (f 15 jC),
regated rafts are formed in the plasma membrane. These macrodomains allow
. Raft aggregation, which could lead to CD36 oligomerization, results in the
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have shown that F-actin co-localizes with glycosphingoli-
pid-enriched membrane microdomains, or raft-associated
molecules, and that co-localization could be disrupted with
removal of cholesterol. Furthermore, Brdickova et al. [56]
have identified a cytoplasmic adapter protein that could act
as a bridge between lipid rafts and the actin cytoskeleton.
Overall, these studies suggest a critical relationship between
membrane rafts and the cytoskeleton. Finally, similar to
thrombin-activated platelets, the calcium ionophore A23187
has been shown to induce changes in platelet shape,
aggregation, and secretion of the granule contents [57,58].
If the increase in cytosolic calcium observed upon cold-
induced activation [18] is the result of calcium leakage from
internal stores due to membrane damage during chilling,
then it could also be necessary to mediate raft aggregation.
Overall, these data suggest that the actin cytoskeleton and
cytosolic calcium could play a significant role in raft
aggregation during cold-induced platelet activation, a hy-
pothesis that we are currently testing.Acknowledgements
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